

**Tumor Board Tuesday – Dr. Shilpa Gupta, 12/13/2022:  
Relapsed Patient with Clear Cell RCC**

Posttest Rationale

- 1. 75-year male with Stage 2 renal cell carcinoma**  
**Experiences relapse (1st relapse)**  
**Clear cell histology**  
**Risk: Poor**  
**Patient has limited mobility and has a difficult time leaving the house**  
**What treatment would you select for this patient?**

- a. Axitinib
- b. Belzutifan
- c. Cabozantinib**
- d. Ipilimumab + nivolumab or Cabozantinib-nivolumab

**Rationale:** Per NCCN guidelines, preferred regimens for first relapse for a risk that is poor/intermediate consists of Axitinib + pembrolizumab, Cabozantinib + nivolumab, Ipilimumab + nivolumab, Lenvatinib + pembrolizumab, and Cabozantinib. Since the patient has limited mobility and ECOG PS 2, oral Cabozantinib is preferred over intravenous IO therapy. Axitinib is category 2B. Belzutifan isn't approved for patients with first relapse for a risk that is poor/intermediate, it is approved for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. Ipilimumab + nivolumab and cabozantinib and nivolumab not preferred since IO is given in an infusion center (travel is involved).

**Reference:** National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Kidney. Kidney Cancer Version 1.2023. 2022 July 27; National Comprehensive Cancer Network. Available from:  
[https://www.nccn.org/professionals/physician\\_gls/pdf/kidney.pdf](https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf)

- 2. How many prognostic factors constitute a poor risk group according to the Memorial Sloan Kettering Cancer Center (MSKCC) Prognostic Model**

- a. No prognostic factors
- b. One or more prognostic factors
- c. Two or more prognostic factors
- d. Three or more prognostic factors**

**Rationale:** According to the Memorial Sloan Kettering Cancer Center (MSKCC) Prognostic Model, poor risk group consists of three or more prognostic factors.

**Reference:** National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Kidney. Kidney Cancer Version 1.2023. 2022 July 27; National Comprehensive Cancer Network. Available from:  
[https://www.nccn.org/professionals/physician\\_gls/pdf/kidney.pdf](https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf)